All In Biotech

Drug Trial Radar · NCT05813795

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)

Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 664 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

664

Actual

Start

Apr 5, 2023

Primary completion

Jun 20, 2024

Study completion Oct 10, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity

Conditions

  • Weight Management

Interventions

  • Ecnoglutide Low DosageDrug

    Subcutaneous Injection

  • Ecnoglutide Medium DosageDrug

    Subcutaneous Injection

  • Ecnoglutide High DosageDrug

    Subcutaneous Injection

  • PlaceboDrug

    Subcutaneous Injection with matched volume

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from baselineTime frame: Week 40
  2. Proportion of subjects with weight loss ≥5% from baselineTime frame: Week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.